

# STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2002 KANSAS

## LIST OF TABLES

### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

## **FOR DUAL ELIGIBLE BENEFICIARIES**

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE D.3. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

## **SUPPLEMENTAL TABLES**

- SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
- SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
- SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
- SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
- SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
- SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

## **APPENDIX TABLE**

- APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
- APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
- APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2  
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	No. of Benes							No. of Bene Mos						
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown		
<b>All</b>	<b>217,700</b>	<b>1,064</b>	<b>28,699</b>	<b>41,075</b>	<b>146,807</b>	<b>55</b>	<b>1,436,539</b>	<b>9,682</b>	<b>281,584</b>	<b>203,247</b>	<b>941,689</b>	<b>337</b>		
<b>Age</b>														
5 and younger	68,538	0	1,380	0	67,158	0	409,334	0	13,134	0	396,200	0		
6-14	63,342	0	4,688	0	58,654	0	449,040	0	47,666	0	401,374	0		
15-20	31,265	0	3,277	7,027	20,961	0	212,589	0	32,463	36,180	143,946	0		
21-44	41,811	1	9,435	32,330	34	11	252,088	6	93,771	158,062	169	80		
45-64	11,678	1	9,918	1,715	0	44	103,788	1	94,549	8,981	0	257		
65-74	681	678	1	2	0	0	6,787	6,765	1	21	0	0		
75-84	235	235	0	0	0	0	1,918	1,918	0	0	0	0		
85 and older	150	149	0	1	0	0	995	992	0	3	0	0		
Unknown	0	0	0	0	0	0	0	0	0	0	0	0		
<b>Gender</b>														
Female	122,429	721	14,929	34,586	72,138	55	791,439	6,646	149,206	173,117	462,133	337		
Male	95,243	343	13,770	6,489	74,641	0	645,050	3,036	132,378	30,130	479,506	0		
Unknown	28	0	0	0	28	0	50	0	0	0	50	0		
<b>Race</b>														
White	135,725	490	20,857	28,104	86,227	47	902,030	4,280	202,582	137,995	556,862	311		
African American	38,565	144	5,357	7,284	25,778	2	263,104	1,450	54,344	37,518	169,785	7		
Other/unknown	43,410	430	2,485	5,687	34,802	6	271,405	3,952	24,658	27,734	215,042	19		
<b>Use of Nursing Facilities<sup>c</sup></b>														
Entire year	552	140	412	0	0	0	4,789	1,070	3,719	0	0	0		
Part year	433	79	352	2	0	0	3,960	594	3,349	17	0	0		
None	216,715	845	27,935	41,073	146,807	55	1,427,790	8,018	274,516	203,230	941,689	337		
<b>Maintenance Assistance Status</b>														
Cash	85,339	687	24,469	24,217	35,966	0	605,549	7,236	249,349	123,516	225,448	0		
Medically needy	4,902	164	1,581	1,552	1,605	0	26,536	975	9,987	7,429	8,145	0		
Poverty-related	102,591	5	296	11,267	90,968	55	596,322	24	2,034	44,760	549,167	337		
Other/unknown	24,868	208	2,353	4,039	18,268	0	208,132	1,447	20,214	27,542	158,929	0		
<b>Managed Care Status</b>														
FFS all year	146,291	891	26,819	24,318	94,220	43	1,207,910	8,781	271,419	152,865	774,575	270		
FFS part year, with Rx claims	25,381	148	1,489	7,640	16,094	10	107,414	797	8,332	27,444	70,782	59		
FFS part year, no Rx claims	46,028	25	391	9,117	36,493	2	121,215	104	1,833	22,938	96,332	8		

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	% with at Least One Rx	Mean No. of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Services	Rx \$ as % of All Services	No. of Benes
All	52.1 %	6.6	\$388	\$58	\$3,234	12.0 %	217,700
<b>Age</b>							
5 and younger	46.6	2.3	89	39	1,686	5.3	68,538
6-14	47.2	4.1	252	62	1,818	13.8	63,342
15-20	54.3	5.6	331	59	3,459	9.6	31,265
21-44	58.5	9.0	576	64	5,289	10.9	41,811
45-64	80.3	37.6	2,243	60	11,270	19.9	11,678
65-74	81.2	36.1	1,838	51	11,092	16.6	681
75-84	75.7	31.9	1,474	46	10,405	14.2	235
85 and older	88.0	42.8	1,666	39	17,055	9.8	150
Unknown	0.0	0.0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>c</sup></b>							
Aged	81.0	36.2	1,737	48	11,792	14.7	1,064
Disabled	80.4	28.4	1,901	67	13,039	14.6	28,699
Adults	52.6	3.9	160	41	2,202	7.3	41,075
Children	46.3	2.9	147	50	1,541	9.5	146,807
Unknown	69.1	14.9	993	66	12,020	8.3	55
<b>Gender</b>							
Female	53.8	7.3	400	55	3,121	12.8	122,429
Male	50.0	5.8	374	65	3,381	11.1	95,243
Unknown	0.0	0.0	0	0	509	0.0	28
<b>Race</b>							
White	56.6	8.2	489	60	3,743	13.1	135,725
African American	45.1	5.0	278	56	2,854	9.8	38,565
Other/unknown	44.5	3.4	172	50	1,983	8.7	43,410
<b>Use of Nursing Facilities<sup>d</sup></b>							
Entire year	98.6	77.9	5,060	65	37,809	13.4	552
Part year	98.2	72.5	4,428	61	41,614	10.6	433
None	51.9	6.3	368	58	3,070	12.0	216,715
<b>Maintenance Assistance Status</b>							
Cash	56.5	10.8	670	62	4,780	14.0	85,339
Medically needy	52.8	8.0	519	65	5,229	9.9	4,902
Poverty related	45.3	2.3	93	41	1,358	6.9	102,591
Other/unknown	65.2	10.2	612	60	5,278	11.6	24,868

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
  - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	Mean No. of Rx	Mean Rx \$	Rx \$ as % of All Services	No. of Rx, % with:					Mean \$, All Services	Benes	Bene Mos	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less				More than 10
All	1.0	\$59	12.0 %	47.9 %	38.2 %	5.6 %	5.4 %	2.1 %	0.7 %	\$490	217,700	1,436,539
<b>Age</b>												
5 and younger	0.4	15	5.3	53.4	42.0	3.2	1.3	0.1	0.0	282	68,538	409,334
6-14	0.6	36	13.8	52.8	37.7	4.8	4.0	0.7	0.1	256	63,342	449,040
15-20	0.8	49	9.6	45.7	40.6	6.6	5.5	1.3	0.3	509	31,265	212,589
21-44	1.5	96	10.9	41.5	36.7	8.7	8.8	3.3	1.0	877	41,811	252,088
45-64	4.2	252	19.9	19.7	20.1	10.8	23.5	18.4	7.5	1,268	11,678	103,788
65-74	3.6	184	16.6	18.8	23.8	9.7	23.8	16.9	7.0	1,113	681	6,787
75-84	3.9	181	14.2	24.3	17.9	10.2	20.0	16.6	11.1	1,275	235	1,918
85 and older	6.5	251	9.8	12.0	10.7	5.3	24.7	24.7	22.7	2,571	150	995
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
<b>Basis of Eligibility<sup>c</sup></b>												
Aged	4.0	191	14.7	19.0	20.5	9.3	23.1	18.0	10.2	1,296	1,064	9,682
Disabled	2.9	194	14.6	19.6	30.3	12.2	21.2	12.1	4.6	1,329	28,699	281,584
Adults	0.8	32	7.3	47.4	39.0	7.2	5.0	1.1	0.2	445	41,075	203,247
Children	0.5	23	9.5	53.7	39.7	3.9	2.3	0.4	0.1	240	146,807	941,689
Unknown	2.4	162	8.3	30.9	27.3	12.7	20.0	5.5	3.6	1,962	55	337
<b>Gender</b>												
Female	1.1	62	12.8	46.2	38.9	5.9	5.6	2.5	0.9	483	122,429	791,439
Male	0.9	55	11.1	50.0	37.3	5.3	5.2	1.7	0.5	499	95,243	645,050
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	285	28	50
<b>Race</b>												
White	1.2	74	13.1	43.4	39.5	6.6	6.7	2.8	1.0	563	135,725	902,030
African American	0.7	41	9.8	54.9	34.9	4.5	3.9	1.5	0.4	418	38,565	263,104
Other/unknown	0.5	28	8.7	55.5	37.2	3.7	2.7	0.7	0.2	317	43,410	271,405
<b>Use of Nursing Facilities<sup>d</sup></b>												
Entire year	9.0	583	13.4	1.4	5.3	3.6	20.5	34.2	35.0	4,358	552	4,789
Part year	7.9	484	10.6	1.8	6.5	9.0	22.9	33.7	26.1	4,550	433	3,960
None	1.0	56	12.0	48.1	38.4	5.6	5.4	2.0	0.6	466	216,715	1,427,790
<b>Maintenance Assistance Status</b>												
Cash	1.5	95	14.0	43.5	35.6	6.9	8.5	4.1	1.3	674	85,339	605,549
Medically needy	1.5	96	9.9	47.2	30.1	7.6	9.3	4.4	1.5	966	4,902	26,536
Poverty related	0.4	16	6.9	54.7	39.6	3.8	1.7	0.2	0.0	234	102,591	596,322
Other/unknown	1.2	73	11.6	34.8	42.9	8.4	9.4	3.2	1.3	631	24,868	208,132

Table ND4

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.5  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	All Rx		Patented Brand-Name Drugs		Off-Patent Brand-Name Drugs		Generic Drugs	
	No. of Rx	Rx \$	No. of Rx	\$ per Rx	No. of Rx	Rx \$	No. of Rx	Rx \$
<b>All</b>	<b>1.0</b>	<b>\$59</b>	<b>0.5</b>	<b>\$47</b>	<b>0.1</b>	<b>\$4</b>	<b>0.4</b>	<b>\$8</b>
<b>Age</b>								
5 and younger	0.4	15	0.2	11	0.0	1	0.2	3
6-14	0.6	36	0.3	28	0.0	3	0.2	4
15-20	0.8	49	0.4	39	0.1	4	0.3	6
21-44	1.5	96	0.7	76	0.1	6	0.7	13
45-64	4.2	252	2.0	198	0.3	16	1.9	39
65-74	3.6	184	1.6	138	0.3	14	1.7	33
75-84	3.9	181	2.0	146	0.2	8	1.7	27
85 and older	6.5	251	2.7	184	0.6	18	3.1	49
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
<b>Basis of Eligibility<sup>d</sup></b>								
Aged	4.0	191	1.8	144	0.3	13	1.9	33
Disabled	2.9	194	1.4	155	0.2	12	1.3	26
Adults	0.8	32	0.3	24	0.1	2	0.4	6
Children	0.5	23	0.2	18	0.0	2	0.2	3
Unknown	2.4	162	1.1	141	0.1	5	1.2	17
<b>Gender</b>								
Female	1.1	62	0.5	48	0.1	4	0.5	9
Male	0.9	55	0.4	44	0.1	4	0.4	7
Unknown	0.0	0	0.0	0	0.0	0	0.0	0
<b>Race</b>								
White	1.2	74	0.6	58	0.1	5	0.5	10
African American	0.7	41	0.3	32	0.1	3	0.3	6
Other/unknown	0.5	28	0.3	22	0.0	2	0.2	4
<b>Use of Nursing Facilities<sup>e</sup></b>								
Entire year	9.0	583	3.9	432	0.8	57	4.2	94
Part year	7.9	484	3.5	365	0.6	37	3.8	82
None	1.0	56	0.5	44	0.1	4	0.4	8
<b>Maintenance Assistance</b>								
<b>Status</b>								
Cash	1.5	95	0.7	75	0.1	6	0.7	13
Medically needy	1.5	96	0.7	76	0.1	6	0.7	15
Poverty related	0.4	16	0.2	12	0.0	2	0.2	3
Other/unknown	1.2	73	0.7	60	0.1	5	0.5	9
<b>\$ per Rx</b>								
<b>All</b>		<b>\$59</b>	<b>0.5</b>	<b>\$47</b>	<b>0.1</b>	<b>\$4</b>	<b>0.4</b>	<b>\$8</b>
<b>Patented Brand-Name Drugs</b>		<b>\$56</b>						
<b>Off-Patent Brand-Name Drugs</b>		<b>\$95</b>						
<b>Generic Drugs</b>		<b>\$57</b>						
<b>\$ per Rx</b>		<b>\$19</b>						

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kansas, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Total	Patented	Off-Patent	Total	Total No. of Rx	Total Rx \$	No.	As % of All Benes	No. of Bene Mos		
																Generic	Brand-Name
Anti-infective Agents	0.3	0.1	0.0	0.1	\$12	\$9	\$1	\$2	\$43	\$70	\$72	\$14	191,057	\$8,275,240	76,303	35.0 %	692,343
Biologicals	0.5	0.4	0.0	0.0	553	463	24	66	1204	1,125	1,332	2,212	1,039	1,251,150	277	0.1	2,263
Antineoplastic Agents	0.5	0.3	0.0	0.2	139	126	2	11	263	448	59	51	3,201	842,345	615	0.3	6,055
Endocrine/Metabolic Drugs	0.5	0.3	0.1	0.2	25	20	2	3	47	72	27	18	124,477	5,829,083	24,821	11.4	232,998
Cardiovascular Agents	1.1	0.4	0.1	0.6	39	26	3	10	34	61	36	15	153,317	5,218,297	13,735	6.3	134,649
Respiratory Agents	0.4	0.3	0.0	0.1	23	17	3	3	52	67	66	22	187,012	9,692,328	44,753	20.6	418,512
Gastrointestinal Agents	0.5	0.3	0.0	0.2	42	37	2	3	82	123	162	16	67,311	5,494,685	13,585	6.2	131,404
Genitourinary Agents	0.3	0.2	0.0	0.1	14	13	0	1	47	58	28	15	17,193	808,358	6,362	2.9	58,054
CNS Drugs	1.0	0.6	0.0	0.3	93	81	3	8	96	129	97	26	237,453	22,764,494	26,008	11.9	246,055
Stimulants/Anti-obesity/Anorexia	0.7	0.4	0.1	0.2	42	30	5	7	60	69	59	38	56,804	3,384,312	8,355	3.8	80,454
Miscellaneous Psychological/Neurological Agents	0.3	0.2	0.0	0.1	34	27	0	7	121	156	0	66	2,205	267,692	794	0.4	7,917
Analgesics and Anesthetics	0.5	0.1	0.0	0.3	24	17	2	5	46	117	70	15	163,511	7,598,754	33,869	15.6	315,475
Neuromuscular Agents	0.8	0.4	0.1	0.3	58	49	3	7	69	110	52	19	125,159	8,613,563	14,969	6.9	147,532
Nutritional Products	0.4	0.0	0.1	0.3	6	0	1	4	16	21	17	15	28,104	449,763	9,588	4.4	76,649
Hematological Agents	0.6	0.2	0.1	0.4	55	48	2	5	92	290	20	14	14,266	1,305,927	2,497	1.1	23,761
Topical Products	0.2	0.1	0.0	0.1	7	4	1	2	32	52	55	16	69,167	2,182,549	34,629	15.9	330,262
Miscellaneous Products	0.3	0.1	0.0	0.2	43	34	6	4	131	238	245	24	3,804	497,276	1,186	0.5	11,512
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	23	0	0	0	2,108	49,364	1,013	0.5	10,493
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,447,188	84,525,180	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Kansas, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Top 10 Drug Groups	Users				Among Users		
	Total Medicaid Rx \$	No. As % of All Benes	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo	
ANTIPSYCHOTICS	\$13,934,230	13,186	6.1 %	136,781	0.6	\$163	\$102
ANTIDEPRESSANTS	7,557,000	25,156	11.6	245,337	0.5	61	31
ANTICONVULSANT	7,376,643	12,137	5.6	124,891	0.7	83	59
ANTIASTHMATIC	4,980,039	32,745	15.0	312,438	0.3	54	16
ULCER DRUGS	4,208,593	12,279	5.6	123,581	0.4	87	34
ANALGESICS - Narcotic	3,624,880	33,517	15.4	323,037	0.3	36	11
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	3,318,570	9,199	4.2	90,563	0.6	60	37
ANTIHISTAMINES	3,093,873	26,098	12.0	257,232	0.3	48	12
ANALGESICS - ANTI-INFLAMMATORY	2,588,913	19,890	9.1	195,330	0.2	53	13
ANTIDIABETIC	2,534,760	6,188	2.8	63,225	0.7	58	40
Total	53,217,501	190,395		1,872,415	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BOE, AND AGE<sup>a,b,c</sup> NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANTIDEPRESSANTS			
	No. of Rx	Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>750,796</b>	<b>\$53,217,501</b>	<b>13,186</b>	<b>6.1 %</b>	<b>136,781</b>	<b>0.6</b>	<b>\$102</b>	<b>25,156</b>	<b>11.6 %</b>	<b>245,337</b>	<b>0.5</b>	<b>\$31</b>
<b>Female</b>	446,147	30,241,109	6,552	5.4	67,785	0.6	95	16,745	13.7	161,494	0.5	31
<b>Disabled</b>	280,882	21,493,031	4,135	27.7	44,911	0.6	112	8,115	54.4	87,411	0.6	36
5 and younger	2,122	101,199	13	2.2	121	0.4	25	8	1.4	77	0.7	13
6-14	12,421	980,691	233	14.8	2,429	0.6	81	298	19.0	3,135	0.5	23
15-20	12,348	974,375	287	22.0	3,055	0.6	90	442	33.8	4,574	0.5	31
21-44	97,140	7,874,219	1,907	35.9	20,698	0.6	111	3,305	62.3	35,831	0.5	35
45-64	156,851	11,562,547	1,695	27.5	18,608	0.7	121	4,062	65.9	43,794	0.6	38
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	165,265	8,748,078	2,417	2.2	22,874	0.5	62	8,630	8.0	74,083	0.4	24
5 and younger	16,105	672,218	42	0.1	468	0.3	46	47	0.1	469	0.4	13
6-14	41,222	2,551,876	704	2.4	7,399	0.6	73	1,283	4.4	12,868	0.5	27
15-20	35,513	2,080,775	756	4.5	7,715	0.5	65	2,223	13.3	21,132	0.4	25
21-44	55,920	2,467,682	741	2.7	5,636	0.3	41	4,508	16.4	34,638	0.3	22
45-64	5,677	343,506	44	3.9	370	0.4	54	335	30.1	2,622	0.4	27
65-74	7,940	477,381	83	17.8	932	0.9	84	146	31.3	1,649	0.6	29
75-84	1,682	92,545	23	15.6	182	0.9	76	46	31.3	380	0.7	31
85 and older	1,206	62,095	24	22.6	172	0.6	54	42	39.6	325	0.8	43
<b>Male</b>	304,649	22,976,392	6,634	7.0	68,996	0.7	109	8,411	8.8	83,843	0.5	31
<b>Disabled</b>	167,152	14,107,188	3,776	27.4	40,212	0.7	125	4,200	30.5	44,116	0.6	34
5 and younger	3,485	209,395	33	4.2	343	0.5	71	17	2.1	179	0.5	12
6-14	34,583	2,584,788	950	30.5	10,268	0.6	84	886	28.4	9,534	0.5	28
15-20	21,041	1,782,079	647	32.8	7,123	0.7	100	597	30.3	6,442	0.6	33
21-44	51,297	5,102,472	1,406	34.1	14,728	0.8	156	1,388	33.6	14,310	0.6	38
45-64	56,746	4,428,454	740	19.7	7,750	0.7	145	1,312	34.9	13,651	0.6	36
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	137,497	8,869,204	2,858	3.5	28,784	0.6	86	4,211	5.2	39,727	0.5	28
5 and younger	22,555	1,005,330	113	0.3	1,230	0.4	69	96	0.3	995	0.3	9
6-14	68,595	4,684,945	1,493	5.0	15,596	0.6	88	1,927	6.5	19,131	0.5	26
15-20	30,998	2,260,303	1,019	9.1	10,083	0.6	85	1,458	13.0	13,774	0.5	32
21-44	8,525	457,157	146	2.9	1,062	0.3	51	505	10.2	3,894	0.4	23
45-64	2,548	162,875	22	3.4	176	0.6	146	135	20.9	1,000	0.5	31
65-74	2,781	211,097	40	18.8	407	1.1	163	58	27.2	620	0.5	27
75-84	771	47,697	7	8.0	64	0.8	137	12	13.6	110	1.0	46
85 and older	724	39,800	18	40.9	166	0.8	59	20	45.5	203	0.8	44
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7A

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANTICONVULSANT					ANTIASTHMATIC					ULCER DRUGS				
	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>12,137</b>	<b>5.6 %</b>	<b>124,891</b>	<b>0.7</b>	<b>\$59</b>	<b>32,745</b>	<b>15.0 %</b>	<b>312,438</b>	<b>0.3</b>	<b>\$16</b>	<b>12,279</b>	<b>5.6 %</b>	<b>123,581</b>	<b>0.4</b>	<b>\$34</b>
<b>Female</b>	6,907	5.6	70,802	0.7	58	17,634	14.4	169,713	0.3	16	8,416	6.9	85,133	0.4	35
<b>Disabled</b>	4,724	31.6	51,060	0.7	64	6,029	40.4	65,906	0.4	23	4,642	31.1	51,839	0.5	45
5 and younger	89	15.2	951	0.6	37	211	36.0	2,233	0.3	15	80	13.7	856	0.4	20
6-14	373	23.8	3,927	0.8	92	402	25.6	4,445	0.3	19	110	7.0	1,175	0.4	25
15-20	362	27.7	3,799	0.8	88	288	22.0	3,172	0.3	15	148	11.3	1,629	0.3	22
21-44	2,052	38.7	22,234	0.7	65	1,916	36.1	21,021	0.3	19	1,556	29.3	17,527	0.4	39
45-64	1,848	30.0	20,149	0.7	55	3,212	52.1	35,035	0.5	27	2,748	44.6	30,652	0.5	51
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	2,183	2.0	19,742	0.6	43	11,605	10.8	103,807	0.2	12	3,774	3.5	33,294	0.3	20
5 and younger	110	0.3	1,047	0.5	50	3,912	12.0	35,481	0.2	10	458	1.4	3,700	0.2	8
6-14	494	1.7	5,126	0.6	49	3,249	11.3	30,665	0.2	13	471	1.6	4,586	0.2	11
15-20	504	3.0	4,921	0.6	56	1,818	10.8	16,729	0.2	12	793	4.7	7,574	0.2	14
21-44	908	3.3	7,095	0.4	30	2,248	8.2	17,356	0.3	11	1,564	5.7	12,706	0.3	23
45-64	61	5.5	478	0.4	32	167	15.0	1,332	0.4	20	199	17.9	1,674	0.4	38
65-74	69	14.8	751	1.0	52	163	34.9	1,857	0.5	27	204	43.7	2,293	0.5	42
75-84	28	19.0	253	0.8	23	31	21.1	265	0.4	20	48	32.7	472	0.5	40
85 and older	9	8.5	71	0.9	25	17	16.0	122	0.6	37	37	34.9	289	0.8	50
<b>Male</b>	5,230	5.5	54,089	0.7	60	15,111	15.9	142,725	0.3	16	3,863	4.1	38,448	0.4	32
<b>Disabled</b>	3,497	25.4	37,357	0.8	68	3,556	25.8	38,445	0.4	22	2,157	15.7	23,410	0.5	40
5 and younger	115	14.5	1,263	0.6	54	410	51.6	4,447	0.3	17	80	10.1	843	0.3	15
6-14	803	25.8	8,817	0.7	57	855	27.4	9,571	0.3	17	153	4.9	1,666	0.4	23
15-20	552	28.0	6,007	0.9	79	360	18.3	4,056	0.3	13	172	8.7	1,864	0.4	30
21-44	1,307	31.7	13,813	0.9	79	602	14.6	6,517	0.4	21	672	16.3	7,370	0.5	41
45-64	720	19.2	7,457	0.7	51	1,329	35.4	13,854	0.5	31	1,080	28.7	11,667	0.5	45
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	1,733	2.1	16,732	0.6	44	11,555	14.2	104,280	0.2	13	1,706	2.1	15,038	0.3	19
5 and younger	160	0.5	1,488	0.5	33	5,643	16.4	49,865	0.2	11	505	1.5	4,006	0.2	8
6-14	831	2.8	8,574	0.6	45	4,222	14.2	39,000	0.3	15	415	1.4	4,070	0.2	11
15-20	493	4.4	4,663	0.7	52	1,263	11.2	12,109	0.3	14	314	2.8	3,101	0.2	17
21-44	169	3.4	1,243	0.4	22	246	5.0	1,676	0.3	17	286	5.8	2,178	0.3	36
45-64	37	5.7	311	0.5	32	63	9.8	406	0.4	22	84	13.0	593	0.4	45
65-74	30	14.1	319	1.0	67	78	36.6	814	0.5	26	66	31.0	740	0.5	48
75-84	5	5.7	56	0.8	29	17	19.3	187	0.4	21	20	22.7	213	0.5	42
85 and older	8	18.2	78	0.9	34	23	52.3	223	0.4	19	16	36.4	137	0.8	52
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7B  
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANALGESICS - Narcotic				STIMULANTS/ANTI-OBESITY/ANOREXIANTS				ANTI-HISTAMINES						
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>33,517</b>	<b>15.4 %</b>	<b>323,037</b>	<b>0.3</b>	<b>\$11</b>	<b>9,199</b>	<b>4.2 %</b>	<b>90,563</b>	<b>0.6</b>	<b>\$37</b>	<b>26,098</b>	<b>12.0 %</b>	<b>257,232</b>	<b>0.3</b>	<b>\$12</b>
<b>Female</b>	24,704	20.2	235,581	0.3	10	2,534	2.1	25,544	0.6	35	15,305	12.5	150,456	0.3	12
<b>Disabled</b>	9,416	63.1	104,978	0.4	19	698	4.7	7,696	0.6	37	4,200	28.1	47,311	0.4	18
5 and younger	50	8.5	524	0.1	2	17	2.9	168	0.4	11	135	23.0	1,460	0.2	5
6-14	188	12.0	2,122	0.1	3	327	20.8	3,562	0.7	39	368	23.4	4,112	0.3	15
15-20	360	27.5	3,947	0.2	4	122	9.3	1,338	0.6	36	306	23.4	3,345	0.3	16
21-44	3,902	73.5	43,561	0.4	16	123	2.3	1,397	0.5	37	1,477	27.8	16,806	0.3	18
45-64	4,916	79.8	54,824	0.5	23	109	1.8	1,231	0.5	35	1,914	31.1	21,588	0.4	21
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	15,288	14.2	130,603	0.2	3	1,836	1.7	17,848	0.6	35	11,105	10.3	103,145	0.2	10
5 and younger	594	1.8	5,836	0.1	1	88	0.3	863	0.4	20	3,088	9.5	29,869	0.2	6
6-14	1,283	4.4	12,828	0.1	1	1,320	4.6	12,951	0.6	35	3,493	12.1	33,950	0.2	13
15-20	3,412	20.4	30,765	0.2	1	304	1.8	3,056	0.6	36	1,981	11.8	18,574	0.2	11
21-44	9,317	34.0	74,718	0.3	4	114	0.4	904	0.4	30	2,246	8.2	17,873	0.2	9
45-64	394	35.4	3,457	0.4	16	7	0.6	45	0.4	31	141	12.7	1,239	0.3	15
65-74	199	42.6	2,282	0.4	13	2	0.4	17	0.5	43	117	25.1	1,321	0.3	17
75-84	44	29.9	409	0.3	7	1	0.7	12	0.2	2	27	18.4	240	0.4	23
85 and older	45	42.5	308	0.6	13	0	0.0	0	0.0	0	12	11.3	79	0.4	18
<b>Male</b>	8,813	9.3	87,456	0.3	14	6,665	7.0	65,019	0.6	37	10,793	11.3	106,776	0.2	12
<b>Disabled</b>	4,025	29.2	43,728	0.4	23	1,916	13.9	20,701	0.7	40	2,258	16.4	25,231	0.3	16
5 and younger	73	9.2	782	0.1	1	64	8.1	594	0.3	18	194	24.4	2,166	0.2	7
6-14	303	9.7	3,411	0.1	6	1,341	43.0	14,436	0.7	41	695	22.3	7,782	0.3	15
15-20	341	17.3	3,762	0.2	4	396	20.1	4,395	0.7	42	319	16.2	3,592	0.3	15
21-44	1,403	34.0	15,293	0.4	24	78	1.9	860	0.6	31	575	13.9	6,450	0.4	19
45-64	1,905	50.7	20,480	0.5	29	37	1.0	416	0.4	37	475	12.6	5,241	0.4	21
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	4,788	5.9	43,728	0.2	4	4,749	5.8	44,318	0.6	36	8,535	10.5	81,545	0.2	10
5 and younger	886	2.6	8,815	0.1	1	277	0.8	2,712	0.4	18	3,678	10.7	35,291	0.2	6
6-14	1,287	4.3	12,992	0.1	2	3,687	12.4	34,242	0.6	37	3,573	12.0	34,337	0.2	13
15-20	1,182	10.5	11,147	0.1	2	757	6.7	7,177	0.6	39	1,009	9.0	9,643	0.3	14
21-44	1,106	22.3	8,009	0.4	12	21	0.4	151	0.4	31	197	4.0	1,520	0.2	11
45-64	215	33.3	1,628	0.5	15	5	0.8	21	0.8	57	38	5.9	335	0.2	13
65-74	70	32.9	778	0.3	19	1	0.5	6	0.8	134	27	12.7	317	0.3	14
75-84	23	26.1	212	0.3	12	0	0.0	0	0.0	0	6	6.8	56	0.3	10
85 and older	19	43.2	147	0.3	5	1	2.3	9	0.8	11	7	15.9	46	0.5	19
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Table ND7C  
 Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BOE, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY				ANTIDIABETIC							
	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All Benes	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Bene Mos	
<b>All</b>	<b>19,890</b>	<b>9.1 %</b>	<b>195,330</b>	<b>0.2</b>	<b>\$13</b>	<b>6,188</b>	<b>2.8 %</b>	<b>63,225</b>	<b>0.7</b>	<b>\$40</b>	<b>217,700</b>	<b>1,436,539</b>
<b>Female</b>	14,251	11.6	139,031	0.3	14	4,423	3.6	45,485	0.7	40	122,429	791,439
<b>Disabled</b>	5,461	36.6	61,113	0.3	25	3,344	22.4	36,661	0.7	42	14,929	149,206
5 and younger	38	6.5	409	0.2	2	0	0.0	0	0.0	0	586	5,365
6-14	109	6.9	1,255	0.2	23	14	0.9	159	0.7	32	1,570	16,126
15-20	224	17.1	2,501	0.2	4	51	3.9	567	0.4	21	1,307	12,982
21-44	2,074	39.1	23,217	0.3	17	808	15.2	8,943	0.6	39	5,306	54,252
45-64	3,016	49.0	33,731	0.4	33	2,471	40.1	26,992	0.7	44	6,160	60,481
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	8,790	8.2	77,918	0.2	6	1,079	1.0	8,824	0.6	32	107,500	642,233
5 and younger	791	2.4	7,533	0.2	2	12	0.0	110	0.5	31	32,657	192,029
6-14	959	3.3	9,556	0.2	3	75	0.3	653	0.7	36	28,843	197,294
15-20	2,216	13.2	20,607	0.2	4	124	0.7	1,060	0.6	37	16,759	103,683
21-44	4,266	15.6	34,949	0.2	6	521	1.9	3,820	0.5	29	27,407	136,588
45-64	279	25.0	2,306	0.3	18	146	13.1	1,117	0.5	28	1,114	5,989
65-74	206	44.1	2,299	0.4	25	145	31.0	1,554	0.7	36	467	4,784
75-84	46	31.3	470	0.4	29	36	24.5	368	0.7	42	147	1,190
85 and older	27	25.5	198	0.6	40	20	18.9	142	0.9	34	106	676
<b>Male</b>	5,639	5.9	56,299	0.2	11	1,765	1.9	17,740	0.7	40	95,243	645,050
<b>Disabled</b>	2,220	16.1	24,488	0.3	18	1,391	10.1	14,600	0.7	40	13,770	132,378
5 and younger	53	6.7	566	0.2	2	0	0.0	0	0.0	0	794	7,769
6-14	163	5.2	1,882	0.2	9	29	0.9	302	0.8	40	3,118	31,540
15-20	208	10.6	2,282	0.2	4	36	1.8	342	0.8	46	1,970	19,481
21-44	709	17.2	7,830	0.3	13	305	7.4	3,150	0.7	39	4,129	39,519
45-64	1,087	28.9	11,928	0.4	27	1,021	27.2	10,806	0.7	40	3,758	34,068
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	3,419	4.2	31,811	0.2	5	374	0.5	3,140	0.7	38	81,473	512,672
5 and younger	872	2.5	8,275	0.2	2	10	0.0	114	0.4	22	34,473	204,121
6-14	836	2.8	8,422	0.1	2	99	0.3	929	0.7	40	29,811	204,080
15-20	989	8.8	9,367	0.2	4	57	0.5	473	0.9	45	11,229	76,443
21-44	514	10.3	3,901	0.2	10	96	1.9	624	0.6	33	4,969	21,729
45-64	125	19.3	931	0.3	20	53	8.2	381	0.6	33	646	3,250
65-74	56	26.3	643	0.3	21	39	18.3	417	0.7	40	213	2,002
75-84	16	18.2	156	0.9	55	18	20.5	182	0.9	44	88	728
85 and older	11	25.0	116	0.5	38	2	4.5	20	0.9	40	44	319
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	28	50

Table ND7D

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2002. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	Rx \$ per Bene Mo	No. of Rx per Bene Mo	No. of All-Year NF Residents	Bene Mos among All-Year NF Residents
<b>All</b>	<b>\$583</b>	<b>9.0</b>	<b>552</b>	<b>4,789</b>
<b>Age</b>				
0-64	639	9.2	412	3,719
65-74	471	8.6	49	465
75-84	360	7.7	39	252
85 and older	308	7.7	52	353
Unknown	0	0.0	0	0
<b>Gender</b>				
Female	568	9.3	338	3,041
Male	609	8.5	214	1,748
Unknown	0	0.0	0	0
<b>Race</b>				
White	578	9.1	454	3,915
African American	559	8.7	68	633
Other/unknown	739	8.4	30	241
<b>Basis of Eligibility<sup>c</sup></b>				
Aged	391	8.1	140	1,070
Disabled	639	9.2	412	3,719
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2002 Medicaid enrollment. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Therapeutic Category	No. of Rx per Bene Mo among Users			\$ per Bene Mo among Users			\$ per Rx			Users							
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total # of Rx	Total Rx \$	No.	As % of All-Year NF Residents					
												No.	Mos				
Anti-infective Agents	0.5	0.2	0.0	0.3	\$32	\$24	\$2	\$5	\$58	\$98	\$66	\$20	1,718	\$99,929	343	62.1 %	3,139
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.8	0.3	0.1	0.4	124	97	1	26	158	291	9	72	138	21,809	20	3.6	176
Endocrine/Metabolic Drugs	1.6	0.8	0.2	0.7	55	40	4	11	34	53	19	16	3,773	127,751	259	46.9	2,305
Cardiovascular Agents	2.3	0.7	0.2	1.4	64	38	5	21	28	53	32	15	6,906	194,139	347	62.9	3,055
Respiratory Agents	1.0	0.4	0.1	0.4	48	27	10	11	50	62	70	28	1,944	96,336	223	40.4	2,009
Gastrointestinal Agents	1.3	0.6	0.0	0.6	76	66	0	9	59	105	88	14	2,960	175,028	266	48.2	2,310
Genitourinary Agents	0.7	0.5	0.0	0.2	39	36	1	3	53	65	34	16	712	37,868	103	18.7	965
CNS Drugs	2.8	1.6	0.3	0.9	338	262	38	38	122	163	147	42	11,338	1,386,982	459	83.2	4,103
Stimulants/Anti-obesity/Anorexia	1.0	0.3	0.1	0.6	44	32	2	10	44	119	20	16	74	3,290	10	1.8	74
Miscellaneous Psychological/Neurological Agents	1.1	1.1	0.0	0.0	127	127	0	0	111	111	0	111	297	33,015	36	6.5	260
Analgesics and Anesthetics	1.3	0.5	0.1	0.6	64	47	6	11	50	90	57	16	3,177	157,866	284	51.4	2,486
Neuromuscular Agents	2.0	0.7	0.2	1.1	105	71	10	24	54	105	55	22	5,798	310,701	313	56.7	2,960
Nutritional Products	1.1	0.0	0.1	1.0	20	0	2	18	18	23	29	17	1,350	24,372	135	24.5	1,243
Hematological Agents	1.3	0.4	0.3	0.6	65	52	5	7	48	135	17	11	1,253	60,757	107	19.4	936
Topical Products	0.5	0.2	0.0	0.3	23	12	4	6	41	59	97	21	1,306	53,681	256	46.4	2,381
Miscellaneous Products	0.4	0.2	0.0	0.2	35	33	0	2	95	193	0	10	75	7,152	23	4.2	205
Unknown Therapeutic Category	0.6	0.0	0.0	0.0	8	0	0	0	14	0	0	0	157	2,215	26	4.7	263
<b>TOTAL NO. OF RX AND RX \$</b>	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	42,976	2,792,891	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2002. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

In Kansas, 0.4 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Top 10 Drug Groups in Nursing Facilities	Users				Among Users		
	Total Medicaid Rx \$	No. of Users	As % of All-Year NF Residents	No. of Bene Mos	No. of Rx per Bene Mo	\$ per Rx	Rx \$ per Bene Mo
ANTIPSYCHOTICS	\$1,049,100	448	81.2 %	4,338	1.4	\$172	\$242
ANTICONVULSANT	235,812	304	55.1	3,039	1.3	62	78
ANTIDEPRESSANTS	216,841	361	65.4	3,466	1.0	61	63
ULCER DRUGS	135,567	206	37.3	1,917	1.0	72	71
ANTIDIABETIC	71,065	147	26.6	1,429	1.1	47	50
ANALGESICS - ANTI-INFLAMMATORY	61,017	138	25.0	1,345	0.7	67	45
ANALGESICS - Narcotic	62,360	245	44.4	2,276	0.7	37	27
ANTIASTHMATIC	53,136	168	30.4	1,553	0.7	46	34
ANTIHYPERLIPIDEMIC	43,913	73	13.2	628	1.0	67	70
ANTIHYPERTENSIVE	39,004	131	23.7	1,211	1.0	31	32
Total	1,967,815	2,221		21,202	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup> NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	All Top 10 Drug Groups						ANTIPSYCHOTICS						ANTICONVULSANT					
	No. of Rx	Rx \$	Users as %			Mean Rx \$	Mean No. of Rx	No. of Users	NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Users as %	No. of Users	NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	
			448	81.2 %	4,338													1.4
<b>All</b>	<b>22,501</b>	<b>\$1,967,815</b>	<b>448</b>	<b>81.2 %</b>	<b>4,338</b>	<b>1.4</b>	<b>\$242</b>	<b>304</b>	<b>55.1 %</b>	<b>3,039</b>	<b>1.3</b>	<b>\$78</b>						
<b>Female</b>	14,680	1,232,518	275	81.4	2,792	1.4	224	198	58.6	2,014	1.2	75						
<b>Disabled</b>	12,251	1,091,563	228	93.4	2,357	1.4	249	170	69.7	1,737	1.2	77						
64 or younger	12,251	1,091,563	228	93.4	2,357	1.4	249	170	69.7	1,737	1.2	77						
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
<b>Other Eligibles</b>	2,429	140,955	47	50.0	435	1.0	90	28	29.8	277	1.3	62						
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
65-74	1,305	85,099	26	86.7	294	0.9	93	17	56.7	198	1.3	70						
75-84	500	26,109	13	52.0	89	1.1	103	8	32.0	55	1.3	44						
85 and older	624	29,747	8	20.5	52	0.8	49	3	7.7	24	1.3	38						
<b>Male</b>	7,821	735,297	173	80.8	1,546	1.5	274	106	49.5	1,025	1.3	83						
<b>Disabled</b>	6,352	635,567	143	85.1	1,284	1.5	304	90	53.6	853	1.3	85						
64 or younger	6,352	635,567	143	85.1	1,284	1.5	304	90	53.6	853	1.3	85						
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
<b>Other Eligibles</b>	1,469	99,730	30	65.2	262	1.2	123	16	34.8	172	1.1	71						
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						
65-74	934	66,437	18	94.7	153	1.4	144	13	68.4	142	1.2	79						
75-84	219	16,751	2	14.3	19	1.6	307	0	0.0	0	0.0	0						
85 and older	316	16,542	10	76.9	90	0.7	46	3	23.1	30	0.9	34						
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0						

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a,b,c,d</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANTIDEPRESSANTS					ULCER DRUGS					ANTIDIABETIC				
	No. of Users	Users as % of All-Year NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All-Year NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Users as % of All-Year NF Residents	No. of Bene Mos among Users	Mean No. of Rx	Mean Rx \$
<b>All</b>	<b>361</b>	<b>65.4 %</b>	<b>3,466</b>	<b>1.0</b>	<b>\$63</b>	<b>206</b>	<b>37.3 %</b>	<b>1,917</b>	<b>1.0</b>	<b>\$71</b>	<b>147</b>	<b>26.6 %</b>	<b>1,429</b>	<b>1.1</b>	<b>\$50</b>
<b>Female</b>	234	69.2	2,273	1.0	64	127	37.6	1,235	0.9	67	98	29.0	988	1.0	45
<b>Disabled</b>	180	73.8	1,815	1.0	66	93	38.1	927	0.9	65	81	33.2	823	1.0	44
64 or younger	180	73.8	1,815	1.0	66	93	38.1	927	0.9	65	81	33.2	823	1.0	44
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	54	57.4	458	1.0	57	34	36.2	308	1.0	72	17	18.1	165	1.2	47
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	22	73.3	255	0.9	57	14	46.7	141	0.9	77	10	33.3	108	1.2	59
75-84	15	60.0	79	1.2	62	6	24.0	52	1.5	75	3	12.0	25	1.4	23
85 and older	17	43.6	124	1.0	53	14	35.9	115	1.0	65	4	10.3	32	1.2	24
<b>Male</b>	127	59.3	1,193	1.0	60	79	36.9	682	1.0	78	49	22.9	441	1.2	62
<b>Disabled</b>	101	60.1	948	1.0	63	61	36.3	526	1.0	79	38	22.6	336	1.2	54
64 or younger	101	60.1	948	1.0	63	61	36.3	526	1.0	79	38	22.6	336	1.2	54
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	26	56.5	245	1.0	51	18	39.1	156	1.0	75	11	23.9	105	1.1	86
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	15	78.9	146	1.0	50	10	52.6	89	1.0	80	6	31.6	58	1.0	83
75-84	3	21.4	21	1.1	39	3	21.4	19	1.0	86	5	35.7	47	1.3	89
85 and older	8	61.5	78	0.9	55	5	38.5	48	1.1	61	0	0.0	0	0.0	0
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.
  - b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
  - c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
  - d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).
- Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY						ANALGESICS - Narcotic						ANTI-ASTHMATIC					
	Users as %			Users as %			Users as %			Users as %			Users as %			Users as %		
	No. of Users	No. of Bene among Users	Mean No. of Rx	Mean Rx \$	No. of Users	Mean No. of Rx	No. of Bene among Users	Mean No. of Rx	Mean Rx \$	Residents	NF	No. of Bene among Users	Mean No. of Rx	No. of Users	Residents	NF	No. of Bene among Users	Mean No. of Rx
<b>All</b>	138	1,345	0.7	\$45	245	0.7	2,276	0.7	\$27	168	30.4 %	1,553	0.7	334	30.4 %	1,553	0.7	\$34
<b>Female</b>	90	900	0.7	50	157	0.8	1,528	0.8	32	101	29.9	972	0.8	37	29.9	972	0.8	37
<b>Disabled</b>	69	724	0.7	53	118	0.9	1,174	0.9	39	76	31.1	761	0.9	40	31.1	761	0.9	40
64 or younger	69	724	0.7	53	118	0.9	1,174	0.9	39	76	31.1	761	0.9	40	31.1	761	0.9	40
65-74	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
75-84	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
85 and older	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	21	176	0.8	38	39	0.4	354	0.4	7	25	26.6	211	0.5	30	26.6	211	0.5	30
64 or younger	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
65-74	9	99	0.6	31	18	0.3	204	0.3	8	5	16.7	57	0.4	17	16.7	57	0.4	17
75-84	3	22	1.2	53	6	0.3	51	0.3	3	10	40.0	84	0.5	21	40.0	84	0.5	21
85 and older	9	55	1.0	44	15	0.7	99	0.7	9	10	25.6	70	0.7	52	25.6	70	0.7	52
<b>Male</b>	48	445	0.6	36	88	0.6	748	0.6	19	67	31.3	581	0.6	29	31.3	581	0.6	29
<b>Disabled</b>	38	365	0.6	32	63	0.6	558	0.6	15	40	23.8	385	0.6	29	23.8	385	0.6	29
64 or younger	38	365	0.6	32	63	0.6	558	0.6	15	40	23.8	385	0.6	29	23.8	385	0.6	29
65-74	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
75-84	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
85 and older	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
<b>Other Eligibles</b>	10	80	0.8	52	25	0.6	190	0.6	28	27	58.7	196	0.7	28	58.7	196	0.7	28
64 or younger	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0
65-74	2	15	0.9	28	8	0.3	72	0.3	54	15	78.9	98	0.8	36	78.9	98	0.8	36
75-84	3	11	1.6	113	8	0.5	51	0.5	24	3	21.4	19	0.8	39	21.4	19	0.8	39
85 and older	5	54	0.6	46	9	0.3	67	0.3	3	9	69.2	79	0.4	16	69.2	79	0.4	16
<b>Unknown</b>	0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BOE, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	ANTIHYPERTENSIVE					ANTIHYPERTENSIVE					Bene Mos among All-Year NF Residents	
	Users as %		Users as %		Mean Rx\$	Users as %		Users as %		Mean Rx\$		
	No. of Users	No. of Bene Users	No. of Bene Users	No. of Bene Users		No. of Users	No. of Bene Users	No. of Bene Users	No. of Bene Users			
<b>All</b>	<b>73</b>	<b>13.2 %</b>	<b>628</b>	<b>1.0</b>	<b>\$70</b>	<b>131</b>	<b>23.7 %</b>	<b>1,211</b>	<b>1.0</b>	<b>\$32</b>	<b>552</b>	<b>4,789</b>
<b>Female</b>	48	14.2	409	1.1	71	78	23.1	751	1.1	33	338	3,041
<b>Disabled</b>	35	14.3	311	1.1	71	55	22.5	556	1.1	34	244	2,324
64 or younger	35	14.3	311	1.1	71	55	22.5	556	1.1	34	244	2,324
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	13	13.8	98	1.1	73	23	24.5	195	1.0	31	94	717
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	5	16.7	54	0.9	72	9	30.0	102	1.0	26	30	310
75-84	3	12.0	17	0.8	43	6	24.0	36	1.0	41	25	154
85 and older	5	12.8	27	1.7	92	8	20.5	57	1.0	35	39	253
<b>Male</b>	25	11.7	219	1.0	67	53	24.8	460	1.0	31	214	1,748
<b>Disabled</b>	18	10.7	161	1.1	64	41	24.4	355	1.0	32	168	1,395
64 or younger	18	10.7	161	1.1	64	41	24.4	355	1.0	32	168	1,395
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Other Eligibles</b>	7	15.2	58	0.8	78	12	26.1	105	0.8	26	46	353
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	5	26.3	42	1.0	99	7	36.8	57	1.0	33	19	155
75-84	1	7.1	10	0.5	22	3	21.4	30	0.7	27	14	98
85 and older	1	7.7	6	0.3	26	2	15.4	18	0.6	6	13	100
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2002. A total of 433 beneficiaries who were in nursing facilities for part of their enrollment and their 3,960 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2002. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2002 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, [http://www.Medi-Span.com/products/product\\_mddb.asp](http://www.Medi-Span.com/products/product_mddb.asp) (May 13 2003).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Center for Medicare and Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11  
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
 KANSAS, 2002

Beneficiary Characteristics	No. of Benes with at Least One Part D Excl Rx	% Benes with at Least One Part D Excl Rx	No. of Part D Excl Rx per Bene	Total No. Part D Excl Rx	Part D Excl Rx \$ per Bene	Total Part D Excl Rx \$	\$ per Part D Excl Rx	Part D Excl Rx \$ as % of All Nonduals Rx \$	Total No. of Benes
<b>Age</b>									
5 and younger	9,764	14.2	0.3	20,046	4	301,088	15	4.9	68,538
6-14	6,052	9.6	0.2	13,574	6	382,012	28	2.4	63,342
15-20	3,211	10.3	0.2	7,728	7	220,648	29	2.1	31,265
21-44	3,892	9.3	0.4	17,166	11	442,340	26	1.8	41,811
45-64	3,309	28.3	2.0	23,349	34	399,426	17	1.5	11,678
65-74	230	33.8	2.5	1,724	32	21,812	13	1.7	681
75-84	68	28.9	2.8	660	29	6,851	10	2.0	235
85 and older	87	58.0	5.9	887	59	8,879	10	3.6	150
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>c</sup></b>									
Aged	385	36.2	3.1	3,271	35	37,542	11	2.0	1,064
Disabled	7,371	25.7	1.6	44,908	39	1,123,994	25	2.1	28,699
Adults	2,362	5.8	0.1	4,928	2	91,553	19	1.4	41,075
Children	16,486	11.2	0.2	31,996	4	529,501	17	2.5	146,807
Unknown	9	16.4	0.6	31	8	466	15	0.9	55
<b>Gender</b>									
Female	15,303	12.5	0.4	51,965	9	1,070,026	21	2.2	122,429
Male	11,310	11.9	0.3	33,169	7	713,030	21	2.0	95,243
Unknown	0	0.0	0.0	0	0	0	0	0.0	28
<b>Race</b>									
White	18,258	13.5	0.5	63,198	11	1,436,904	23	2.2	135,725
African American	3,587	9.3	0.3	10,537	5	176,358	17	1.6	38,565
Other/unknown	4,768	11.0	0.3	11,399	4	169,794	15	2.3	43,410
<b>Use of Nursing Facilities<sup>d</sup></b>									
Entire year	373	67.6	8.0	4,443	100	55,447	12	2.0	552
Part year	293	67.7	6.4	2,754	81	35,114	13	1.8	433
None	25,947	12.0	0.4	77,937	8	1,692,495	22	2.1	216,715
<b>Maintenance Assistance Status</b>									
Cash	12,016	14.1	0.6	51,837	13	1,103,018	21	1.9	85,339
Medically needy	609	12.4	0.4	2,070	19	91,739	44	3.6	4,902
Poverty related	9,878	9.6	0.2	18,040	3	283,123	16	3.0	102,591
Other/unknown	4,110	16.5	0.5	13,187	12	305,176	23	2.0	24,868

Table ND11

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
KANSAS, 2002

Beneficiary Characteristics	No. Rx per Bene Mo.	Rx \$ per Bene Mo.	\$ per Rx	Barbiturate \$ per Bene Mo.	Benzodiazepine \$ per Bene Mo.	No. of Bene Mos
All	0.1	\$1	\$21	\$0	\$0	1,436,539
<b>Age</b>						
5 and younger	0.0	1	15	0	0	409,334
6-14	0.0	1	28	0	0	449,040
15-20	0.0	1	29	0	0	212,589
21-44	0.1	2	26	0	1	252,088
45-64	0.2	4	17	0	1	103,788
65-74	0.3	3	13	0	0	6,787
75-84	0.3	4	10	0	0	1,918
85 and older	0.9	9	10	0	0	995
Unknown	0.0	0	0	0	0	0
<b>Basis of Eligibility<sup>c</sup></b>						
Aged	0.3	4	11	0	0	9,682
Disabled	0.2	4	25	0	1	281,584
Adults	0.0	0	19	0	0	203,247
Children	0.0	1	17	0	0	941,689
Unknown	0.1	1	15	0	0	337
<b>Gender</b>						
Female	0.1	1	21	0	0	791,439
Male	0.1	1	21	0	0	645,050
Unknown	0.0	0	0	0	0	50
<b>Race</b>						
White	0.1	2	23	0	0	902,030
African American	0.0	1	17	0	0	263,104
Other/unknown	0.0	1	15	0	0	271,405
<b>Use of Nursing Facilities<sup>d</sup></b>						
Entire year	0.9	12	12	0	3	4,789
Part year	0.7	9	13	0	2	3,960
None	0.1	1	22	0	0	1,427,790
<b>Maintenance Assistance Status</b>						
Cash	0.1	2	21	0	1	605,549
Medically needy	0.1	3	44	0	0	26,536
Poverty related	0.0	0	16	0	0	596,322
Other/unknown	0.1	1	23	0	0	208,132

Table ND12

Nondual Beneficiaries

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

- a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002.
  - b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
  - c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
  - d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.
- Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.13  
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
FOR SELECTED DRUG CATEGORIES AMONG NONDUALS<sup>a,b,c</sup>  
KANSAS, 2002

Drug Category	No. Users	Rx \$ per User	Total Rx \$	Rx \$ as % of All Part D Excl Rx \$	Total No. Rx.	\$ per Rx	No. Rx as % of All Part D Excl Rx
<b>All</b>	<b>31,554</b>	<b>\$57</b>	<b>\$1,783,056</b>	<b>100.0 %</b>	<b>85,134</b>	<b>\$21</b>	<b>100.0 %</b>
Anorexia or weight loss/gain	33	270	8,907	0.5	89	100	0.1
Fertility drugs	2	47	93	0.0	2	47	0.0
Drugs for cosmetic purposes	0	0	0	0.0	0	0	0.0
Cough and cold medications	10,571	39	411,340	23.1	16,858	24	19.8
Vitamins and minerals	3,576	88	313,130	17.6	16,253	19	19.1
Non-prescription drugs	13,245	22	297,211	16.7	29,856	10	35.1
Barbiturates	511	48	24,596	1.4	4,052	6	4.8
Benzodiazepines	2,451	177	434,667	24.4	14,273	30	16.8
Other Part D Excl Rx Drugs	1,165	252	293,112	16.4	3,751	78	4.4

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all non-dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2002. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2002. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Center for Medicare and Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1

CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
NONDUAL BENEFICIARIES, KANSAS, 2002

Beneficiary Characteristics	No. of Beneficiaries					No. of Beneficiaries					
	All	Aged	Disabled	Adults	Children	All	Aged	Disabled	Adults	Children	Unknown
<b>All</b>	<b>253,060</b>	<b>1,089</b>	<b>28,845</b>	<b>47,578</b>	<b>175,493</b>	<b>2,169,944</b>	<b>10,775</b>	<b>292,562</b>	<b>346,213</b>	<b>1,519,998</b>	<b>396</b>
<b>Age</b>											
5 and younger	83,540	0	1,387	0	82,153	711,787	0	14,141	0	697,646	0
6-14	73,823	0	4,718	0	69,105	667,992	0	50,638	0	617,354	0
15-20	35,471	0	3,292	7,979	24,200	297,743	0	34,313	58,623	204,807	0
21-44	47,057	1	9,459	37,551	35	368,797	6	96,512	272,008	191	80
45-64	12,078	1	9,988	2,045	0	112,829	1	96,957	15,555	0	316
65-74	690	687	1	2	0	7,149	7,127	1	21	0	0
75-84	243	243	0	0	0	2,286	2,286	0	0	0	0
85 and older	158	157	0	1	0	1,361	1,355	0	6	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0
<b>Gender</b>											
Female	142,123	739	14,992	40,055	86,282	1,203,694	7,441	154,075	294,807	746,975	396
Male	110,893	350	13,853	7,523	89,167	966,135	3,334	138,487	51,406	772,908	0
Unknown	44	0	0	0	44	115	0	0	0	115	0
<b>Race</b>											
White	157,006	507	20,975	32,436	103,041	1,338,257	4,961	211,533	232,013	889,391	359
African American	45,428	144	5,368	8,663	31,251	413,587	1,543	55,472	69,815	286,745	12
Other/unknown	50,626	438	2,502	6,479	41,201	418,100	4,271	25,557	44,385	343,862	25
<b>Use of Nursing Facilities<sup>c</sup></b>											
Entire year	568	144	424	0	0	5,560	1,420	4,140	0	0	0
Part year	438	81	355	2	0	4,286	736	3,533	17	0	0
None	252,054	864	28,066	47,576	175,493	2,160,098	8,619	284,889	346,196	1,519,998	396
<b>Maintenance Assistance Status</b>											
Cash	95,044	692	24,506	27,442	42,404	859,550	7,448	255,129	211,918	385,055	0
Medically needy	6,544	175	1,653	2,426	2,290	39,237	1,297	11,390	13,473	13,077	0
Poverty related	124,231	6	318	12,783	111,069	996,301	41	2,322	70,900	922,642	396
Other/unknown	27,241	216	2,368	4,927	19,730	274,856	1,989	23,721	49,922	199,224	0
<b>Managed Care Status</b>											
FFS all year	146,291	891	26,819	24,318	94,220	1,207,910	8,781	271,419	152,865	774,575	270
FFS part year, with Rx claims	25,381	148	1,489	7,640	16,094	250,897	1,645	16,371	69,100	163,671	110
FFS part year, no Rx claims	46,028	25	391	9,117	36,493	430,888	254	3,939	78,682	347,997	16
MC all year, with Rx claims	382	15	85	97	185	2,130	73	548	348	1,161	0
MC all year, no Rx claims	34,978	10	61	6,406	28,501	278,119	22	285	45,218	232,594	0

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene Mo(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2  
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup>  
 NONDUAL BENEFICIARIES, KANSAS, 2002

	Bene Mos in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos	No. of Benes	No. of Bene Mos
<b>All</b>	<b>253,060</b>	<b>2,169,944</b>	<b>217,700</b>	<b>1,436,539</b>	<b>0</b>	<b>733,405</b>
FFS all year	146,291	1,207,910	146,291	1,207,910	0	0
FFS part year, with Rx claims	25,381	250,897	25,381	107,414	0	143,483
FFS part year, with no Rx claims	46,028	430,888	46,028	121,215	0	309,673
MC all year, with Rx claims	382	2,130	0	0	0	2,130
MC all year, with no Rx claims	34,978	278,119	0	0	0	278,119

Source: Data for this table are from the MAX 2002 file for Kansas, released by CMS in 07/2006. This table was produced on 04/19/2007.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Center for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.